Imaging of lung cancer resistance to EGFR tyrosine kinase inhibitors through Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3

被引：0
|
作者：
Zannetti, A. [1 ]
Iommelli, F. [1 ]
Fonti, R. [1 ]
Papaccioli, A. [1 ]
Sommella, J. [1 ]
Lettieri, A. [1 ]
Bianco, R. [2 ]
Tortora, G. [2 ]
Salvatore, M. [3 ]
Del Vecchio, S. [3 ]
机构：
[1] CNR, Inst Biostruct & Bioimages, Naples, Italy
[2] Univ Naples Federico II, Dept Endocrinol & Mol & Clin Oncol, Naples, Italy
[3] Univ Naples Federico II, Dept Biomorphol & Funct Sci, Naples, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2008年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S187 / S187
页数：1
相关论文
共 50 条
  • [1] Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-XL modulation of inositol trisphosphate receptor type 3
    Zannetti, Antonella
    Iommelli, Francesca
    Fonti, Rosa
    Papaccioli, Angela
    Sommella, Jvana
    Lettieri, Anna
    Pirozzi, Giuseppe
    Bianco, Roberto
    Tortora, Giampaolo
    Salvatore, Marco
    Del Vecchio, Silvana
    CLINICAL CANCER RESEARCH, 2008, 14 (16) : 5209 - 5219
  • [2] Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer
    Jin, Junfei
    Xiong, Ying
    Cen, Bo
    ANTI-CANCER DRUGS, 2017, 28 (10) : 1141 - 1149
  • [3] Imaging of Bcl-2/Bcl-xL dysregulated apoptotic program in NSCLC cells resistant to EGFR tyrosine kinase inhibitors
    Zannetti, A.
    Iommelli, F.
    Fonti, R.
    Lettieri, A.
    Pirozzi, G.
    Bianco, R.
    Tortora, G.
    Salvatore, M.
    Del Vecchio, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S476 - S476
  • [4] Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer
    Lu, Yingjie
    Bian, Dongliang
    Zhang, Xuelin
    Zhang, Huibiao
    Zhu, Zhenghong
    MOLECULAR MEDICINE REPORTS, 2021, 23 (01) : 1 - 9
  • [5] Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-2/Bcl-xL inhibitors
    Toivanen, Kirsi L. J.
    Murumagi, Astrid
    Arjama, Mariliina A.
    Merikoski, Nanna J.
    Salmikangas, Sami I.
    Kallioniemi, Olli P.
    Bohling, Tom O.
    Sihto, Harri J.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [6] Resistance to apoptosis induced by Bcl-2 and or Bcl-xL favours metastatic progression of breast cancer
    Fernández, Y
    Mañas, S
    España, L
    Torregrosa, A
    Fabra, A
    Sierra, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S11 - S11
  • [7] Understanding and overcoming resistance of MDM2 and Bcl-2/Bcl-xL small-molecule inhibitors in human cancer
    Wang, Shaomeng
    Hoffman-Luca, Cassandra Gianna
    Bai, Longchuan
    Lu, Jianfeng
    McEachem, Donna
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [8] Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with Diminished Platelet Toxicity
    Kargbo, Robert B.
    ACS MEDICINAL CHEMISTRY LETTERS, 2023, 14 (09): : 1156 - 1158
  • [9] Targeting Bcl-2/Bcl-xl for small cell lung cancer treatment with LP-118
    Lee, Ling-Ling
    Chen, Huan
    Zhu, Cong
    Chen, Yao
    Feldmeier, Brianna
    Shen, Yue
    Chen, Yu
    Anthony, Stephen P.
    Tan, Fenlai
    Chen, Yi
    Dai, Bing
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Differential expression of Bcl-2 and Bcl-xL in human small cell lung cancer (SCLC) and adenocarcinoma of the lung (ACL)
    Li, E
    Xiao, H
    Vikram, B
    LABORATORY INVESTIGATION, 2001, 81 (01) : 223A - 223A
12345